Featured Research

from universities, journals, and other organizations

Study finds known lung cancer oncogenes also drive colorectal cancer

Date:
December 17, 2013
Source:
University of Colorado Cancer Center
Summary:
A study shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.

A University of Colorado Cancer Center study published online ahead of print in the journal Molecular Cancer Research shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.

Related Articles


"When you have known oncogenes that are already targeted by FDA-approved drugs, it just made sense to look for these oncogenes in other cancers," says Marileila Varella Garcia, PhD, investigator at the CU Cancer Center and professor at the CU School of Medicine. "By rethinking the way we understand cancers -- as their genetic mutations and not just as the sites where they live in the body -- we see that a therapy that targets a specific mutation may show benefit in treating any other cancer that shares the same mutation," says Dara Aisner, MD, PhD, investigator at the CU Cancer Center and molecular pathologist at the CU School of Medicine.

In this study, Garcia, Aisner and colleagues used the technique known as fluorescence in situ hybridization (FISH) to test for the oncogenic gene rearrangements in 236 tumor samples of colorectal cancer collected from patients enrolled in a large, Australian clinical trial. The work found one patient carrying the ALK rearrangement, confirming previous findings, and demonstrated the first finding of ROS1 as an oncogenic driver of colorectal cancer -- in this case found in 2 of the 236 tumor samples.

"Even though the percentage of colorectal cancer patients with these gene rearrangements is small, the benefit to these few patients could be dramatic. It's worth the work. It's worth following this line of reasoning to its conclusion to see if colorectal cancer patients will also benefit from drugs proved effective in lung cancer," says Robert C. Doebele, MD, PhD, investigator at the CU Cancer Center and assistant professor at the CU School of Medicine.

Surprisingly, these gene alterations tended to co-exist in colorectal tumors along with other molecular alterations - tumors that were positive for ALK rearrangements were also positive for another well-defined molecular alternation known as KRAS; ROS1 mutations occurred in one specimen along with the known, oncogenic mutation, BRAF.

"Conventional wisdom is that one molecular driver alteration exists throughout all tumor cells in a specimen, and that it's mutually exclusive of other alterations. We found that neither of those axioms held true -- some tumor regions had different alterations, and even more surprisingly, in some regions both alterations were seen. These findings show that you can find more than one alteration in a single specimen, and that not all cells within a single tumor are necessarily driven by the same oncogene," Aisner says.

The group writes that "identification of ALK and ROS1 oncogenes may open new therapeutic options for CRC," specifically with the class of drugs known as tyrosine-kinase inhibitors (TKIs) shown to "turn off" ALK and ROS1 gene mutations thereby killing or slowing the growth of cancer cells. For example, the drug crizotinib was approved by the FDA in 2011 to treat ALK-positive lung cancer, and this drug or others that are in development to treat ALK+ and ROS1+ cancers may have similar benefit in CRC.

"This is a case in which we have all the background science -- we know that when ALK and ROS1 improperly fuse with other genes, the result can be oncogenic. We have drugs that target these oncogenes. And we even have tests to determine who has the gene rearrangements and so should benefit from these drugs. The important piece missing was finding these oncogenes in other cancers, and now we've filled in that piece in colorectal cancer," Aisner says.


Story Source:

The above story is based on materials provided by University of Colorado Cancer Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. D. L. Aisner, T. T. Nguyen, D. D. Paskulin, A. T. Le, J. Haney, N. Schulte, F. Chionh, J. Hardingham, J. Mariadason, N. Tebbutt, R. C. Doebele, A. J. Weickhardt, M. Varella-Garcia. ROS1 and ALK Fusions in Colorectal Cancer, with Evidence of Intra-tumoral Heterogeneity for Molecular Drivers. Molecular Cancer Research, 2013; DOI: 10.1158/1541-7786.MCR-13-0479-T

Cite This Page:

University of Colorado Cancer Center. "Study finds known lung cancer oncogenes also drive colorectal cancer." ScienceDaily. ScienceDaily, 17 December 2013. <www.sciencedaily.com/releases/2013/12/131217134031.htm>.
University of Colorado Cancer Center. (2013, December 17). Study finds known lung cancer oncogenes also drive colorectal cancer. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2013/12/131217134031.htm
University of Colorado Cancer Center. "Study finds known lung cancer oncogenes also drive colorectal cancer." ScienceDaily. www.sciencedaily.com/releases/2013/12/131217134031.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) — Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) — Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) — A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins